Biogen shares fall as rival spinal muscular atrophy drug shows promise

Biogen tumbled as much as 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received the item.

Spinal musclar atrophy is actually a rare genetic condition that will prevents the body via developing a muscle protein called SMN. Without the protein, muscles atrophy in addition to also movement is actually impaired. Babies with the condition often die within 18 months.

Over the weekend, PTC Therapeutics presented promising research at the CureSMA researcher conference in Dallas. Over a stretch of 182 days, 0 percent of babies with Type 1 SMA that will received the therapy demonstrated improvement in their conditions, including the ability to control their heads, roll or sit.

PTC Therapeutics’ experimental drug poses a serious threat to Spinraza, the first drug that will was approved to treat SMA. PTC is actually co-developing the drug with Roche.

Sales of Biogen’s multiple sclerosis drugs have been declining due to the competition via several brand new generic in addition to also brand name MS drugs.

“Our HOLD-rating on Biogen reflects our concerns about declining sales inside the multiple sclerosis franchise in addition to also slowing U.S. sales growth in Spinraza. We see the [Bigoen’s] MS products facing heighten competition in 2018 in addition to also 2019 via generics in addition to also brand new brand name entrants,” David Toung, Argus senior analyst, wrote in a note.

Biogen has two brand new drugs inside the pipeline, including an MS drug the item is actually developing in partnership with Alkermes that will could help Biogen maintain its leadership in MS treatment. although Toung noted the brand new drugs “are at least two years away reaching the market.”

PTC Therapeutics shares skyrocketed Monday to a brand new 52-week high of $52.95. Recently the stock was changing hands up about 25 percent at $46.83 in robust volume.

Novartis also is actually a pursuing an SMA therapy inside the wake of its acquisition of Avexis. Its stock fell more than 2 percent in trading Monday.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

4 × one =